Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15371492 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA7CA9 | |
| Hydrogen Peroxide SCHEMBL29099624 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL6745083 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL5016671 | 0.73 | TSHR (0.34) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL8304556 | 0.73 | HTT (0.33) | ALDH1A1CA1CA2TSHRCYP1A2 | |
| SCHEMBL6110086 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL12164462 | 0.73 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL840498 | 0.71 | CA1 (0.39) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL24394208 | 0.71 | ALDH1A1 (0.43) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL95838 | 0.71 | CYP2C19 (0.35) | ALDH1A1CA1CA2TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | ALDH1A1 1365/4885CA1 3204/4885CA2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.